摘要
目的观察口服曲美他嗪治疗老年心力衰竭的疗效。方法选取我院2012年收治住院的心力衰竭患者62例,随机分成两组,常规治疗组及曲美他嗪治疗组,每组31例。观察患者疗效、预后及超声心动图参数情况。结果治疗后常规治疗组好转率为42%,曲美他嗪治疗组为65%,曲美他嗪治疗组好转率高于常规治疗组,差异有统计学意义(P<0.05)。两组患者治疗后左室射血分数、左室舒张末内径均有好转,曲美他嗪治疗组好转率高于常规治疗组,差异均有统计学意义(P<0.05)。1年内常规治疗组因心力衰竭加重死亡2例,心律失常死亡2例,猝死1例,病死率为16.1%。曲美他嗪治疗组因心力衰竭加重死亡2例,心律失常死亡1例,猝死1例,病死率为12.9%。结论曲美他嗪治疗老年人心力衰竭的治疗效果较好,用药方便,无明显不良反应,患者耐受性好。
Objective To observe the effect of trimetasidine oral treating elderly heart failure. Methods 62 cases with heart failure patients in our hospital 2012 were randomly divided into two groups： the conventional treatment group and trim- etazidine treatment group, each group 31 cases. The efficacy, prognosis and echocardiographic parameters circumstances in the group were observed. Results After treatment, the conventional treatment group improved 42%, trimetazidine treatment group was 65%, which was higher than the conventional treatment group （P 〈0. 05）. After the treatment, the left ventricular ejec- tion fraction and left ventricular end - diastolic diameter were improved, trimetazidine treatment group were higher than the con- ventional treatment group （P 〈 0. 05）. 1 year conventional treatment group, 2 patients died due to worsening heart failure, 2 patients died due to arrhythmias, one case of sudden death, mortality was 16. 1%. Trimetazidine treatment group, 2 patients died due to worsening heart failure, one case death of arrhythmia, one case of sudden death, mortality was 12. 9%. Conclu- sion Trimetazidine treatment of elderly heart failure treatment is better, convenient medication, no significant adverse reac- tions, patients tolerated.
出处
《临床合理用药杂志》
2013年第36期43-44,共2页
Chinese Journal of Clinical Rational Drug Use
